Efficacy
Tegsedi significantly delays disease progression vs placebo(1)

Efficacy

Efficacy

Tegsedi significantly delays disease progression vs placebo(1)

Tegsedi significantly delays disease progression vs placebo1


Earlier initiation of Tegsedi demonstrated better outcomes in neuropathic progression2*


Tegsedi significantly stabilise neuropathy-related QoL vs placebo1,2


Tegsedi sustains neuropathy-related QoL stabilisation over 2 years1,2


Read more
About Tegsedi

About Tegsedi

For your hATTR patients with stage 1 or 2 polyneuropathy, what matters is now

Mode of Action

Mode of Action

Tegsedi targets TTR production in hATTR1,2

Safety

Safety

Up to 6 years of experience in clinical trials and over 220 patients years4

Administration

Administration

Tegsedi is administered as a convenient weekly subcutaneous injection1,2

Tegsedi CONNECT

Tegsedi CONNECT

Empowering independence for people living with hATTR

Prescribing information

Prescribing information

References

mNIS+7: modified Neuropathy Impairment Score+7 composite score
*No statistical analysis performed 
Tegsedi 284mg is the same as the study drug inotersen sodium 300mg. TTR: transthyretin; OLE: open label extension

  1. Tegsedi Summary of Product Characteristics. April 2021.
  2. Benson MD et al. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018;379(1):22–31.
  3. Brannagan TH, Wang AK, Coelho T, et al. Eur J Neurol. 2020;27(8):1374-1381. doi:10.1111/ene.14285
  4. Coelho T et al. Efficacy and safety with >3 years of inotersen treatment for the polyneuropathy of hereditary transthyretin amyloidosis. OPR15, 7th Congress of the European Academy of Neurology 2021, 19-22 June 20.